Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.
about
How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsAntiviral drug resistance of human cytomegalovirus.Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.The biology of cytomegalovirus drug resistanceMolecular Determinants for the Inactivation of the Retinoblastoma Tumor Suppressor by the Viral Cyclin-dependent Kinase UL97.Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasmaThe genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.Novel method based on "en passant" mutagenesis coupled with a gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations.Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibilityDesign and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach.Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives.Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions.Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus.Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations.Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivoThe time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection.Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients.Human cytomegalovirus pUL97 drug-resistance mutations in congenitally neonates and HIV-infected, no-drug-treated patients
P2860
Q28069489-ED0E0E53-0C89-49D1-9E91-80938174B868Q30430427-1DD42B37-7BD0-4C33-AF5B-B37282AB35D8Q34483416-543562D6-1CE0-4F72-B327-F98420B4D5D1Q34687313-3FC7340B-272B-48E6-AF61-F1DC2A5D6B80Q34975934-91B2BE08-A419-4852-A8FB-22018B62CC41Q35596269-096ECCAB-C34A-45C4-A9D7-78C726D2941FQ35684511-4BC2EE37-132B-4FC0-9C23-562940686AC7Q35925834-910F7EEE-20F0-4D03-8CE6-2B666A8789F9Q35943076-81DB70C8-9C92-4069-80BE-40AB922393A3Q37173390-2A9CFECF-01ED-44AD-BF2D-8BC2D2B79575Q37264338-349C36E9-C6D3-4559-AACD-7AEC019FF2E1Q37671946-809BEEBE-7B83-465A-8179-0E01D7938C67Q37713957-B682B48E-004C-4D6A-B1DF-732F9CC5169BQ38227257-23888D32-BF2F-41CD-9817-B7BE956822F0Q38282979-00A5ED92-8552-4C40-A7D6-C429DD7766B3Q38324789-6FCFBEC5-5C1D-4601-8330-5850910E3D19Q38370342-2B4E048C-2619-4427-AAF2-E1DEAE6EB8DCQ38779846-4A25820F-3297-483B-8DBD-678CA85F198FQ38818062-8DA87B45-8591-4094-A9AD-C8D3AACCF477Q39074863-E563EE5D-08BC-42DA-94C0-CEDAECAD5BDFQ39155340-8FFD5789-B14C-4DC8-87F9-5188D9702BE5Q40414645-21484D46-CF93-4D45-A803-9043EF9E00C3Q40483485-9859D7F9-00FD-4C76-B62E-F0425EAAC084Q40649144-208D25A0-409B-4602-9F88-F870E8F7AB77Q41060769-0A4A84F3-A9E4-496C-8D49-DBF8E4CEC87DQ41657330-9FD7478C-4A41-48DE-8991-1ADA96FB2F21Q42141568-0CA58245-6296-480B-8E37-B76F924FDFF1Q42280383-03FE7595-1E8C-424A-BF32-97F34D2D6D15Q43869508-FDB8A777-0FFE-4932-A923-79D574ABDB32Q58824913-4AAB298F-8704-454C-9A3E-F2F0AF86B386
P2860
Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Recombinant phenotyping of cyt ...... ts for ganciclovir resistance.
@ast
Recombinant phenotyping of cyt ...... ts for ganciclovir resistance.
@en
type
label
Recombinant phenotyping of cyt ...... ts for ganciclovir resistance.
@ast
Recombinant phenotyping of cyt ...... ts for ganciclovir resistance.
@en
prefLabel
Recombinant phenotyping of cyt ...... ts for ganciclovir resistance.
@ast
Recombinant phenotyping of cyt ...... ts for ganciclovir resistance.
@en
P2860
P356
P1476
Recombinant phenotyping of cyt ...... ts for ganciclovir resistance.
@en
P2093
Sunwen Chou
P2860
P304
P356
10.1128/AAC.00186-10
P407
P577
2010-04-12T00:00:00Z